Your browser doesn't support javascript.
Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
Li, Tingting; Han, Xiaojian; Gu, Chenjian; Guo, Hangtian; Zhang, Huajun; Wang, Yingming; Hu, Chao; Wang, Kai; Liu, Fengjiang; Luo, Feiyang; Zhang, Yanan; Hu, Jie; Wang, Wang; Li, Shenglong; Hao, Yanan; Shen, Meiying; Huang, Jingjing; Long, Yingyi; Song, Shuyi; Wu, Ruixin; Mu, Song; Chen, Qian; Gao, Fengxia; Wang, Jianwei; Long, Shunhua; Li, Luo; Wu, Yang; Gao, Yan; Xu, Wei; Cai, Xia; Qu, Di; Zhang, Zherui; Zhang, Hongqing; Li, Na; Gao, Qingzhu; Zhang, Guiji; He, Changlong; Wang, Wei; Ji, Xiaoyun; Tang, Ni; Yuan, Zhenghong; Xie, Youhua; Yang, Haitao; Zhang, Bo; Huang, Ailong; Jin, Aishun.
  • Li T; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Han X; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Gu C; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Guo H; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Zhang H; Key Laboratory of Medical Molecular Virology, Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Wang Y; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
  • Hu C; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
  • Wang K; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Liu F; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Luo F; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Zhang Y; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Hu J; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Wang W; Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, 400010, China.
  • Li S; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
  • Hao Y; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Shen M; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Huang J; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Long Y; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Song S; Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, 400010, China.
  • Wu R; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Mu S; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Chen Q; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Gao F; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Wang J; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Long S; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Li L; Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, 150000, China.
  • Wu Y; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Gao Y; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Xu W; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Cai X; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Qu D; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Zhang Z; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Zhang H; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Li N; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Gao Q; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Zhang G; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • He C; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Wang W; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Ji X; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Tang N; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Yuan Z; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Xie Y; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Yang H; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Zhang B; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
  • Huang A; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400010, China.
  • Jin A; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, 400010, China.
Nat Commun ; 12(1): 6304, 2021 11 02.
Artigo em Inglês | MEDLINE | ID: covidwho-1500462
Preprint
Este artigo de periódico científico é provavelmente baseado em um preprint previamente disponível, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver preprint
ABSTRACT
Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (mAbs), 58G6, 510A5 and 13G9, with high neutralizing potency blocking authentic SARS-CoV-2 virus display remarkable efficacy against authentic B.1.351 virus. Surprisingly, structural analysis has revealed that 58G6 and 13G9 both recognize the steric region S470-495 on the RBD, overlapping the E484K mutation presented in B.1.351. Also, 58G6 directly binds to another region S450-458 in the RBD. Significantly, 58G6 and 510A5 both demonstrate prophylactic efficacy against authentic SARS-CoV-2 and B.1.351 viruses in the transgenic mice expressing human ACE2 (hACE2), protecting weight loss and reducing virus loads. Together, we have evidenced 2 potent neutralizing Abs with unique mechanism targeting authentic SARS-CoV-2 mutants, which can be promising candidates to fulfill the urgent needs for the prolonged COVID-19 pandemic.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Tipo de estudo: Estudo prognóstico Tópicos: Variantes Limite: Animais / Humanos Idioma: Inglês Revista: Nat Commun Assunto da revista: Biologia / Ciência Ano de publicação: 2021 Tipo de documento: Artigo País de afiliação: S41467-021-26539-7

Similares

MEDLINE
LILACS
LIS
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Tipo de estudo: Estudo prognóstico Tópicos: Variantes Limite: Animais / Humanos Idioma: Inglês Revista: Nat Commun Assunto da revista: Biologia / Ciência Ano de publicação: 2021 Tipo de documento: Artigo País de afiliação: S41467-021-26539-7